Insulet Total Depreciation and Amortization - Cash Flow 2010-2025 | PODD
Insulet annual/quarterly total depreciation and amortization - cash flow history and growth rate from 2010 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
- Insulet total depreciation and amortization - cash flow for the quarter ending March 31, 2025 was $0.022B, a 15.43% increase year-over-year.
- Insulet total depreciation and amortization - cash flow for the twelve months ending March 31, 2025 was $0.200B, a 10.45% increase year-over-year.
- Insulet annual total depreciation and amortization - cash flow for 2024 was $0.081B, a 10.99% increase from 2023.
- Insulet annual total depreciation and amortization - cash flow for 2023 was $0.073B, a 15.19% increase from 2022.
- Insulet annual total depreciation and amortization - cash flow for 2022 was $0.063B, a 10.1% increase from 2021.
| Insulet Annual Total Depreciation and Amortization - Cash Flow (Millions of US $) |
|
|---|---|
| 2024 | $81 |
| 2023 | $73 |
| 2022 | $63 |
| 2021 | $57 |
| 2020 | $55 |
| 2019 | $28 |
| 2018 | $16 |
| 2017 | $14 |
| 2016 | $14 |
| 2015 | $16 |
| 2014 | $12 |
| 2013 | $12 |
| 2012 | $11 |
| 2011 | $9 |
| 2010 | $5 |
| 2009 | $11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $21.551B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $239.054B | 28.75 |
| Boston Scientific (BSX) | United States | $154.291B | 38.63 |
| Stryker (SYK) | United States | $149.710B | 31.30 |
| EssilorLuxottica (ESLOY) | France | $128.407B | 0.00 |
| Medtronic (MDT) | Ireland | $110.260B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.622B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.216B | 26.92 |
| ResMed (RMD) | United States | $37.817B | 28.40 |
| Agilent Technologies (A) | United States | $33.696B | 21.97 |
| GE HealthCare Technologies (GEHC) | United States | $33.311B | 15.81 |
| Terumo (TRUMY) | Japan | $27.198B | 35.33 |
| Koninklijke Philips (PHG) | Netherlands | $23.033B | 16.16 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.358B | 11.79 |
| Baxter (BAX) | United States | $15.708B | 11.73 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.095B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.558B | 22.82 |
| Lantheus Holdings (LNTH) | United States | $5.573B | 14.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.039B | 18.04 |
| Perrigo (PRGO) | Ireland | $3.660B | 9.28 |
| Haemonetics (HAE) | United States | $3.526B | 16.06 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.280B | 27.25 |
| ICU Medical (ICUI) | United States | $3.251B | 23.97 |
| GN Store Nord (GNNDY) | Denmark | $2.346B | 19.43 |
| LeMaitre Vascular (LMAT) | United States | $1.910B | 42.70 |
| QuidelOrtho (QDEL) | United States | $1.901B | 13.07 |
| AtriCure (ATRC) | United States | $1.598B | 0.00 |
| Acuren (TIC) | United States | $1.263B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.216B | 12.34 |
| Green Thumb Industries (GTBIF) | United States | $1.111B | 25.00 |
| Neogen (NEOG) | United States | $1.057B | 13.53 |
| BioLife Solutions (BLFS) | United States | $1.015B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.003B | 12.82 |
| Kestra Medical Technologies (KMTS) | United States | $0.908B | 0.00 |
| InMode (INMD) | Israel | $0.898B | 9.05 |
| CeriBell (CBLL) | United States | $0.698B | 0.00 |
| Owens & Minor (OMI) | United States | $0.607B | 5.04 |
| Evolus (EOLS) | United States | $0.587B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.578B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.557B | 0.00 |
| Valneva SE (VALN) | France | $0.468B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.459B | 0.00 |
| Surmodics (SRDX) | United States | $0.413B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.396B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.335B | 12.32 |
| SNDL (SNDL) | Canada | $0.321B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.281B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| ZimVie (ZIMV) | United States | $0.250B | 11.34 |
| Sanara MedTech (SMTI) | United States | $0.249B | 0.00 |
| Quanterix (QTRX) | United States | $0.241B | 0.00 |
| Brainsway (BWAY) | Israel | $0.233B | 61.65 |
| Biote (BTMD) | United States | $0.227B | 6.37 |
| Canopy Growth (CGC) | Canada | $0.226B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.220B | 65.33 |
| OraSure Technologies (OSUR) | United States | $0.215B | 0.00 |
| Omeros (OMER) | United States | $0.205B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.197B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.181B | 14.71 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Organigram Global (OGI) | Canada | $0.177B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.175B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.138B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.81 |
| Jin Medical (ZJYL) | China | $0.108B | 0.00 |
| Veru (VERU) | United States | $0.102B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Fonar (FONR) | United States | $0.088B | 11.32 |
| Quipt Home Medical (QIPT) | United States | $0.084B | 0.00 |
| MacroGenics (MGNX) | United States | $0.083B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.078B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.075B | 0.00 |
| Zynex (ZYXI) | United States | $0.074B | 0.00 |
| Apyx Medical (APYX) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Agape ATP (ATPC) | $0.063B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.061B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 59.98 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.25 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Safety Shot (SHOT) | United States | $0.023B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |